WASHINGTON — Food and Drug Administration Commissioner Scott Gottlieb said that it’s not his agency’s job to regulate drug prices — but on Wednesday morning, he used his bully pulpit to condemn a “rigged payment scheme” that he said he fears is keeping some generic drugs out of the market.
Speaking to a group of hundreds at a conference run by America’s Health Insurance Plans, Gottlieb spoke about the challenges facing biosimilar manufacturers, which make generic biologic drugs. He called on the audience primarily of insurance professionals to do something, offering a few concrete suggestions.
“We have a lot of finger-pointing that ignores shared complicity for pricing practices that are eroding trust in both payors and innovators,” Gottlieb said. “I hope that you’ll act before that trust is eroded completely.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
